(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Brazil's agricultural research agency gets cannabis research greenlight - 2What is colostrum? And should you be taking it?
- 3US FDA declines to approve Corcept's drug for rare hormonal disorder
- 4Step by step instructions to Safeguard Your Teeth During Sports Exercises
- 5Former hostage Eitan Mor on Hamas: ‘They will not give up until the last Israeli is gone'
- We may be witnessing the messy death of a star in real time
- Shah Capital pushes for Novavax sale, warns of proxy fight
- Watch the Geminid meteor shower peak tonight from the comfort of home with this free livestream
- Sea Ice Hits New Low in Hottest Year on Record for the Arctic
- Flying without a Real ID? That'll soon cost you $45, TSA says.
- Former defense minister Gallant vacated home over security threat under Shin Bet direction
- I decided to become a single mother by choice. I wasn't ready to stop dating.
- At least 36 dead in major fire in Hong Kong residential blocks
- AI is making spacecraft propulsion more efficient – and could even lead to nuclear-powered rockets
